◎ Sugi Atlas

Atlas / Drug / Cortisone Acetate

Cortisone Acetate

drug
On this page

Also known as CortateCortelanCortisonaCortisoneCortisone aceticumCortistabCortisylCortoneNSC-49420SID50103888SID855514SID90341460SID170464685SID144207031C0164817

Summary

Cortisone Acetate (CHEMBL1650) is an approved small molecule (ATC S01BA03); indicated across 46 conditions including eye disorder and atopic eczema.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: S01BA03 (+1 more)
  • Indications: 46 conditions
  • Clinical trials: 18
  • Chemistry: 402.5 Da · C23H30O6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1650
NameCortisone Acetate
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5745
ATCS01BA03, H02AB10
Molecular formulaC23H30O6
Molecular weight402.5
InChIKeyITRJWOMZKQRYTA-RFZYENFJSA-N

SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O

IUPAC name: [2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Cortate, Cortelan, Cortisona, Cortisone, Cortisone acetate, Cortisone aceticum, Cortistab, Cortisyl, Cortone, NSC-49420, SID50103888, SID855514

Patent coverage: 4,136 distinct patent families (15,942 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: RecQ-like DNA helicase BLM, Androgen receptor, Glucocorticoid receptor, Protein farnesyltransferase, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C15.75Ki1778nMCHEMBL_ACT_7706300
AR5.55AC502810nMCHEMBL_ACT_25203700
NR3C15.41IC503911nMCHEMBL_ACT_7706299
P084825Potency10000nMCHEMBL_ACT_4857825

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

46 indications (44 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
eye disorder4MONDO:0005328EFO:0005752
atopic eczema4MONDO:0004980EFO:0000274
lymphoma4MONDO:0005062EFO:0000574
pneumonia4MONDO:0005249EFO:0003106
meningeal tuberculosis4MONDO:0006042EFO:1000039
dermatitis herpetiformis4MONDO:0015614EFO:1000684
erythema multiforme4MONDO:0006545EFO:1000694
frozen shoulder4MONDO:0006763EFO:1000941
posterior uveitis4MONDO:0006918EFO:1001119
tenosynovitis4MONDO:0004855EFO:1001435
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
psoriatic arthritis4MONDO:0011849EFO:0003778
nephrotic syndrome4MONDO:0005377EFO:0004255
ophthalmic herpes zoster4MONDO:0005883EFO:0007403
pulmonary tuberculosis4MONDO:0006052EFO:1000049
peptic ulcer disease4MONDO:0004247HP:0004398
subacute thyroiditis4MONDO:0006982EFO:1001194
dermatomyositis4MONDO:0016367EFO:0000398
rheumatoid arthritis4MONDO:0008383EFO:0000685
Stevens-Johnson syndrome4MONDO:0018229EFO:0004276
autoimmune thrombocytopenic purpura4MONDO:0008558EFO:0007160
iritis4MONDO:0006814EFO:1000997
polymyositis4MONDO:0019127EFO:0003063
gout4MONDO:0005393EFO:0004274
contact dermatitis4MONDO:0005480EFO:0005319
seborrheic dermatitis4MONDO:0006608EFO:1000764
thrombocytopenia4MONDO:0002049HP:0001873
aplastic anemia4MONDO:0015909HP:0001915
sympathetic ophthalmia4MONDO:0019198EFO:1001205
non-autoimmune hemolytic anemia4MONDO:0021559EFO:0005558
leukemia4MONDO:0005059EFO:0000565
hypercalcemia disease4MONDO:0001566HP:0003072
synovitis4MONDO:0002400EFO:0008997
exfoliative dermatitis4MONDO:0043233EFO:0009456
epicondylitis4MONDO:0001875EFO:1001896
iridocyclitis4MONDO:0004773HP:0001094
chronic primary adrenal insufficiency4MONDO:0015129MONDO:0015128
enteritis4MONDO:0043579MONDO:0043579
asthma4MONDO:0004979MONDO:0004979
osteoarthritis4MONDO:0005178MONDO:0005178
allergic disease4MONDO:0005271MONDO:0005271
congenital adrenal hyperplasia4MONDO:0018479MONDO:0008728
systemic lupus erythematosus4MONDO:0007915MONDO:0007915
angioedema3MONDO:0010481EFO:0005532
rotator cuff syndrome1MONDO:0007028EFO:1001250

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

PhaseTrials
Not specified11
PHASE42
PHASE32
PHASE2/PHASE31
PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03760835PHASE4RECRUITINGCongenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
NCT02639039PHASE4COMPLETEDCortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study
NCT01447160PHASE3UNKNOWNEffectiveness of Facet Joint Infiltration in Low Back Pain
NCT01843530PHASE3COMPLETEDRandomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema
NCT03580148PHASE2/PHASE3COMPLETEDBMA vs Cortisone for Glenohumeral Osteoarthritis
NCT01771328PHASE2UNKNOWNContinuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
NCT00279903PHASE1COMPLETEDIs Botox Effective in Relieving Pain From Knee Osteoarthritis?
NCT02196155Not specifiedRECRUITINGBotulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis
NCT01400022Not specifiedCOMPLETEDTopical 0.05% Clobetasol Propionate in Vaseline Versus UVA-1 Phototherapy in Vulvar Lichen Sclerosus
NCT02091830Not specifiedCOMPLETEDNon-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients
NCT02855866Not specifiedCOMPLETEDInterest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy
NCT02918136Not specifiedCOMPLETEDSafety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears
NCT03082339Not specifiedCOMPLETEDCortisone and QTc-Interval
NCT03410355Not specifiedTERMINATEDBone Marrow Aspirate Concentrate Use in Hip Osteoarthritis
NCT04077190Not specifiedCOMPLETEDSafety and Efficacy of Adult Adipose-Derived Stem Cell Injection Into Partial Thickness Rotator Cuff Tears
NCT05188820Not specifiedCOMPLETEDComparison of IntraArticular Platelet-Rich-Plasma to Corticosteroid Injections for Patients With Zygapophyseal Joint (Z-Joint) Low Back Pain Confirmed by Dual Intra-Articular Local Anesthetic Injections
NCT06082271Not specifiedCOMPLETEDComparative, Randomized Study on the Anti-inflammatory and Regenerative Efficacy of a New Medical Device (DM) Based on Hydrolyzed Collagen Peptides in Patients With Femoro-acetabular Impingement Undergoing Hip Arthroscopy
NCT06737445Not specifiedCOMPLETEDCorticosteroid Injection, Extracorporeal Shock Wave Therapy, and Radiofrequency Ablation for Chronic Plantar Fasciitis:

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 16

This page pulls from 16 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot